Document is current
Any future updates will be listed below
-
Authors
Lapi, Francesco https://orcid.org/0000-0002-4342-9128
Marconi, Ettore
Grattagliano, Ignazio
Rossi, Alessandro
Fornasari, Diego
Magni, Alberto
Lora Aprile, Pierangelo
Cricelli, Claudio
-
Funding
Funding for this research was provided by:
Italian College of General Practitioners and Primary Care
- License Information
-
More Information
Article History
Received: 3 June 2022
Accepted: 11 July 2022
First Online: 30 July 2022
Declarations
:
: FL and EM provided consultancies in protocol preparation for epidemiological studies and data analyses for Angelini, Pfizer, and GSK. AR, IG, AM, PLA, and CC provided clinical consultancies for Angelini, Pfizer, and GSK. DF has no conflict of interest to disclose.
: According to a by-law on the classification and implementation of observational drug-related research, as issued by the Italian National Drug Agency (an entity belonging to the Italian Ministry of Health), the present study does not require approval by an Ethics Committee in Italy (Italian Drug Agency note of 3 August 2007). This study followed the principles of the Declaration of Helsinki and compliant with the ENCePP (European Network of Centres for Pharmacoepidemiology and Pharmacovigilance) Guide on Methodological Standards in Pharmacoepidemiology.
: The database is fully anonymized.
: Not applicable.
Free to read: This content has been made available to all.
